Status:
COMPLETED
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
Lead Sponsor:
ORA, Inc.
Conditions:
Allergic Rhinitis
Allergic Conjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed expos...
Eligibility Criteria
Inclusion
- provide written informed consent and signed HIPAA form;
- be able and willing to follow all instructions and attend the study visits;
- if female and of childbearing potential, be not pregnant, nursing or planning a pregnancy, be willing to submit a pregnancy test at Visit 1 and at exit visit, and to use adequate method of birth control
- have a positive history of seasonal allergic rhinitis to ragweed;
- have a positive skin test reaction to ragweed of within the past 24 months;
- manifest sufficient allergic rhinitis symptoms during ragweed exposure in the ABC
Exclusion
- known intolerance or allergy to antihistamines or corticosteroids;
- have a compromised lung function at Visit 1;
- develop a compromised lung function at Visits 2-6
- have any presence of active sinus or nasal infection at any visit;
- have experienced an acute upper or lower respiratory tract infection or acute sinusitis within 30 days of visit 1;
- have significant nasal anatomical deformities or any condition that does not allow subject to breathe through the nose (includes, but is not limited to: septal deviation, septal perforations, nasal polyps, rhinitis medicamentosa)
- have had any nasal surgical intervention in the past;
- have a known history of glaucoma
- have planned surgery (nasal, ocular or systemic) during the trial period or within 30 days thereafter;
- inability or refusal to discontinue contact lens wear during all visits;
- use disallowed medications during the study or appropriate pre-study washout period
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01439815
Start Date
September 1 2011
End Date
October 1 2011
Last Update
April 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ora, Inc.
Andover, Massachusetts, United States, 01810